DOST launches PHL’s first human skin 3D bioprinting lab in Iloilo

1 of 2

By Rjay Zuriaga Castor 

Iloilo is at the forefront of transformative technology in engineering tissues for disease modeling and drug screening through the first-ever bioprinting laboratory in the country.

The Department of Science and Technology (DOST) launched its agency-funded “Three-dimensional Bioprinted Human Skin Equivalent” laboratory on Thursday.

The bioprinting laboratory located in Jaro, Iloilo City is the product of a collaboration between DOST and Pharma GalenX Innovations, Inc., an Iloilo-based pharmaceutical company.

Through its Business Innovation through S&T for Industry (BIST) Program, DOST funded Pharma GalenX Innovations, Inc. a grant of P10.75 million to acquire 3D bioprinting technology for the in-vitro biocompatibility studies.

Science Secretary Renato Solidum Jr. said the establishment of Pharma GalenX’s bioprinting laboratory is “a testament to the successful synergy between industry and government in advancing cutting-edge research in the Philippines.”

“Through our commitment to research, innovation, education, and collaboration, the DOST contributes to the development of a robust healthcare system that benefits everyone,” he added.

The laboratory’s primary focus is on developing a human skin equivalent (HSE) using 3D bioprinting technology for studies involving topical formulations. It also aims to address gaps in the supply and development of a more efficient system for product testing.

One of the practical uses of this facility is to print human skin to be used as an alternative to animal testing of products.

The laboratory is equipped with state-of-the-art tools, including a 3D bioprinter, an ultra-cold freezer, a microplate reader, CO2 incubators, and microscopes with fluorescence capabilities, among other advanced equipment.

The laboratory facility in Jaro, Iloilo City will house the in-vitro biocompatibility assays and the bioprinting of HSE.

DOST VI Regional Director Engr. Rowen R. Gelonga, Pharma GalenX Innovations Inc. President Jan Vincent N. Sollesta, and other stakeholders signed a memorandum of agreement for the funding of the project in March last year.

Pharma GalenX Innovations, Inc. is the second recipient of the DOST-BIST Program in Western Visayas, following Herbanext Laboratories, Inc. in Bago City, Negros Occidental.